Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Chelidamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.44 |
| ▸ | GRIN2A known ✓ | Q12879 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.95 |
| ▸ | BLM | P54132 | 2/20 | 0.95 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chelidamic Acid SCHEMBL742928 | 0.97 | ALOX15 (1.00) | ALOX15BLMNFKB1SMN1; SMN2ALDH1A1 | |
| Chelidamic Acid SCHEMBL9658074 | 0.95 | ALOX15 (0.95) | ALOX15BLMNFKB1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14634236 | 0.83 | ALOX15 (0.72) | ALOX15BLMNFKB1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13075694 | 0.78 | ALOX15 (0.65) | ALOX15BLMNFKB1SMN1; SMN2ALDH1A1 | |
| Chelidamic Acid SCHEMBL1535360 | 0.75 | ALOX15 (0.60) | ALOX15BLMNFKB1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4264907 | 0.75 | ALOX15 (0.61) | ALOX15BLMNFKB1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13872418 | 0.74 | SMN1; SMN2 (0.61) | ALOX15BLMNFKB1SMN1; SMN2ALDH1A1 | |
| Orotic Acid SCHEMBL16916880 | 0.73 | ALDH1A1 (0.95) | ALOX15BLMNFKB1SMN1; SMN2ALDH1A1 | |
| Orotic Acid SCHEMBL29592552 | 0.73 | ALDH1A1 (0.95) | ALOX15BLMNFKB1SMN1; SMN2ALDH1A1 | |
| Orotic Acid SCHEMBL119625 | 0.73 | ALDH1A1 (0.95) | ALOX15BLMNFKB1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5683793-A | Ink jet transparencies | XEROX CORPORATION (US) | 1997-11-04 | — | — | US | claimed |
| US-5589277-A | INK JET PRINTING, AQUEOUS INKS, FAST DRYING | XEROX CORPORATION (US) | 1996-12-31 | — | — | US | claimed |
| EP-0667246-A1 | Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
| US-20250214985-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250163040-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2025-05-22 | — | — | US | disclosed |
| US-12258339-B2 | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | CORNELL UNIVERSITY (US) | 2025-03-25 | — | — | US | disclosed |
| EP-4458418-A2 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | Cornell University (US) | 2024-11-06 | — | — | EP | disclosed |
| US-12103922-B2 | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | CORNELL UNIVERSITY (US) | 2024-10-01 | — | — | US | disclosed |
| EP-3600452-B1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | UNIV CORNELL (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240254085-A1 | CHELATORS FOR RADIOMETALS AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-08-01 | — | — | US | disclosed |
| US-RE49918-E1 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| WO-2001017999-A2 | AMINO-TRIAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000050470-A2 | CATALYSTS CONTAINING N-PYRROLYL SUBSTITUTED NITROGEN DONORS | EASTMAN CHEMICAL COMPANY (US) | 2000-08-31 | — | — | WO | disclosed |
| US-5757408-A | PRINTING IMAGE ON SUBSTRATE COATED WITH AMINO-ACID DERIVATIVE ADDITIVE; QUICK DRYING OF INK, OPTICAL DENSITY, NONCURLING | XEROX CORPORATION (US) | 1998-05-26 | — | — | US | disclosed |
| US-5683793-A | Ink jet transparencies | XEROX CORPORATION (US) | 1997-11-04 | — | — | US | disclosed |
| US-5589277-A | INK JET PRINTING, AQUEOUS INKS, FAST DRYING | XEROX CORPORATION (US) | 1996-12-31 | — | — | US | disclosed |
| EP-0667246-A1 | Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0046653-B1 | METHOD FOR CONVERTING CARBOXYLIC ACID GROUPS TO TRICHLOROMETHYL GROUPS | THE DOW CHEMICAL COMPANY (US) | 1984-05-16 | — | — | EP | disclosed |
| US-4419514-A | Method for converting carboxylic acid groups to trichloromethyl groups | THE DOW CHEMICAL COMPANY (US) | 1983-12-06 | — | — | US | disclosed |
| EP-0046653-A1 | Method for converting carboxylic acid groups to trichloromethyl groups | THE DOW CHEMICAL COMPANY (US) | 1982-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163040-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, FOLH1, KLK3 | MEN1 12/4885GRIN2A 2528/4885ALOX15 4875/4885 |
| US-12258339-B2 | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | PSMA1, FOLH1, KLK3 | MEN1 12/4885GRIN2A 2528/4885ALOX15 4875/4885 |
| US-12103922-B2 | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | PSMA1, KLK3, FOLH1 | MEN1 15/4885GRIN2A 2597/4885ALOX15 4866/4885 |
| US-20250214985-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, FOLH1, KLK3 | MEN1 12/4885GRIN2A 2528/4885ALOX15 4875/4885 |
| US-20240254085-A1 | CHELATORS FOR RADIOMETALS AND METHODS OF MAKING AND USING SAME | RXFP3, SLC39A3, NR4A3 | MEN1 306/4885GRIN2A 2875/4885ALOX15 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.